Liu Sheng-wen, Qiao Shu-bin, Liu Dong-qing
Coronary Heart Disease Center, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical and Peking Union Medical College, Beiqing, China.
Zhonghua Yi Xue Za Zhi. 2009 Nov 3;89(40):2843-6.
Visfatin is a new novel proinflammatory adipocytokine affecting insulin resistance by binding to insulin receptor. To investigate whether visfatin stimulates monocyte chemotactic protein-1 (MCP-1) and interleukin-6 (IL-6) production in human umbilical vein endothelial cells (HUVEC) and mediates insulin receptor (IR) is involved in are not known.
Cultured HUVEC was treated with different doses and durations of visfatin. Furthermore, HUVEC was pretreated with hydroxy-2-naphthalenylmethylphosphonic acid trisacetoxymethyl ester (HNMPA-(AM)3), a specific inhibitor of IR followed by visfatin (100 ng/ml) treatment. Enzyme-linked immunosorbent assay (ELISA) were used to measure MCP-1 and IL-6 production in HUVEC. Real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) was used for determining MCP-1 and IL-6 mRNA expression.
Visfatin significantly dose- and time- dependently up-regulated protein production of MCP-1 and IL-6 in HUVEC. We therefore found visfatin- induced MCP-1 and IL-6 production and gene expression in HUVEC were inhibited by HNMPA-(AM)3.
Visfatin induces endothelial MCP-1 and IL-6 production in HUVEC in a dose and time-dependently manner. This action appears to be mediated via insulin receptor pathway.
内脂素是一种新型促炎脂肪细胞因子，通过与胰岛素受体结合影响胰岛素抵抗。内脂素是否刺激人脐静脉内皮细胞（HUVEC）产生单核细胞趋化蛋白-1（MCP-1）和白细胞介素-6（IL-6）以及胰岛素受体（IR）是否参与其中尚不清楚。
用不同剂量和作用时间的内脂素处理培养的HUVEC。此外，先用IR特异性抑制剂三乙酰氧基甲基羟-2-萘基甲基膦酸酯（HNMPA-(AM)3）预处理HUVEC，然后用内脂素（100 ng/ml）处理。采用酶联免疫吸附测定（ELISA）法检测HUVEC中MCP-1和IL-6的产生。采用实时定量逆转录聚合酶链反应（RT-PCR）法测定MCP-1和IL-6 mRNA表达。
内脂素显著剂量和时间依赖性地上调HUVEC中MCP-1和IL-6的蛋白产生。因此，我们发现HNMPA-(AM)3可抑制内脂素诱导的HUVEC中MCP-1和IL-6的产生及基因表达。
内脂素以剂量和时间依赖性方式诱导HUVEC产生内皮MCP-1和IL-6。这一作用似乎是通过胰岛素受体途径介导的。
